Objective To observe the application of continuous renal replacement therapy (CRRT) and heparin anticoagulation in patients with HFRS, and to explore a more suitable anticoagulant strategy.
Methods Eighty-five severe-type patients (severe group) and 71 critical-type patients (critical group) were enrolled in this study. The frequency of CRRT was compared between the two groups; the frequency of CRRT treated with and without heparin anticoagulation and the frequency of hemorrhage and channel blood clotting induced by the two anticoagulant strategies were observed.
Results The frequency of CRRT in the critical group was higher than that in the severe group (P ＜ 0.001). The frequency of CRRT initiated during the overlapping phases in the critical group was significantly higher than that of the severe group (P = 0.032). The total times of CRRT was 103, and 70 of them were treated with heparin anticoagulation. The frequencies of hemorrhage induced by heparin anticoagulation and no heparinization were 16 and 0, respectively, and the frequencies of channel blood clotting were 2 and 4, respectively.
Conclusions CRRT has been used extensively in the critical-type patients with HFRS. The heparin anticoagulation and no anticoagulant strategies should be used more rationally in patients treated with CRRT, according to the clinical characteristics of the disease.
1. Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans and animals, China. Emerg Infect Dis 2010;16(8):1195-1203.
2. Luo CW, Chen HX. Epidemiological characteristics and the strategy of vaccination on hemorrhagic fever with renal syndrome in the last 10 years, in China. Zhonghua Liu Xing Bing Za Zhi (Chin) 2008; 29(10):1017-1019.
3. Ma C, Yu P, Nawaz M, Zuo S, Jin T, Li Y, et al. Hantaviruses in rodents and humans, Xi’an, PR China. J Gen Virol 2012; 93(Pt 10):2227-2236.
4. Schmaljohn CS, Hasty SE, Dalrymple JM, LeDuc JW, Lee HW, von Bonsdorff CH, et al. Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome. Science 1985; 227(5690):1041-1044.
5. Welzel TM, Zeier M, Darai G, Ritz E. Hantavirus infection--new threats by an old virus. Nephrol Dial Transplant 1998; 13(11): 2731-2733.
6. Ma Y, Liu B, Yuan B, Wang J, Yu H, Zhang Y, et al. Sustained high level of serum VEGF at convalescent stage contributes to the renal recovery after HTNV infection in patients with hemorrhagic fever with renal syndrome. Clin Dev Immunol 2012; 2012:812386.
7. Song G. Manual for prevention and cure of hemorrhagic fever with renal syndrome. Beijing: People’s Health Press.1998.
8. Ghahramani N, Shadrou S, Hollenbeak C. A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure. Nephrology (Carlton) 2008; 13(7):570-578.
9. Lins RL, Elseviers MM, Van der Niepen P, Hoste E, Malbrain ML, Damas P, et al. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transplant 2009; 24(2):512-518.
10. Dellinger RP, Lew MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guideline for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39(2):165-228.
11. Chinese Medical Association to severe medicine branch: Guidelines for blood purification in ICU. 2009. (Accessed November 15, 2011 at http://www.csccm.org/cn/news.asp?id=121.html.)
12. Ostermann M, Dickie H, Tovey L, Treacher D. Heparin algorithm for anticoagulation during continuous renal replacement therapy. Crit Care 2010; 14(3):419.
13. Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11(4):218.
14. Bai XF, Xu ZK. Hemorrhagic Fever with Renal Syndrome, ed 1. Beijing: People’s Medical Publishing House. 2013.
15. Hoste EA, De Corte W. Implementing the kidney disease: improving global outcomes/acute kidney injury guidelines in ICU patients. Curr Opin Crit Care 2013; 19(6):544-553.
16. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care 2009; 24(1):129-140.
17. Chen WC. Possible interventional therapies in severe sepsis or septic shock. Acta Anaesthesiologica Taiwanica 2012; 50(2):74-77.
18. Huang YH, Liu CC, Wang ST, Lei HY, Liu HL, Lin YS, et al. Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol 2001; 63(3):247-251.
19. Levi M, Löwenberg EC. Thrombocytopenia in critically ill patients. Semin Thromb Hemost 2008; 34(5):417-424.
20. Vanderschueren S, De Weerdt A, Malbrain M, Vankersschaever D, Frans E, Wilmer A, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000; 28(6):1871-1876.